Back to top

Analyst Blog

Allergan Inc. (AGN - Analyst Report) is scheduled to report fourth quarter 2013 results before the opening bell on Feb 5.

Last quarter, Allergan had posted an earnings surprise of +1.65%. We expect the company to beat expectations in the fourth quarter as well.

Why a Likely Positive Surprise?

Our proven model shows that Allergan is likely to beat earnings because it has the right combination of two key ingredients.

Positive Zacks ESP: The Earnings ESP (Expected Surprise Prediction), which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is +0.75%. This is a very meaningful and leading indicator of a likely positive earnings surprise.

Zacks Rank #2 (Buy): Note that stocks with Zacks Rank #1, #2 and #3 have a significantly higher chance of beating earnings estimates. We caution against stocks with Zacks Ranks #4 and #5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revision momentum.

The combination of Allergan’s Zacks Rank #2 (Buy) and an earnings ESP of +0.75% makes us confident of an earnings beat on Feb 5.

What is Driving the Better-than-Expected Earnings?

Allergan has delivered positive earnings surprises in the last three quarters with an average beat of 1.80%.

Botox and Restasis should continue to boost revenues. The specialty pharmaceuticals segment should see strong sales and facial aesthetics should also perform well.

Other Stocks to Consider

Allergan is not the only company looking up this earnings season. We also see likely earnings beats coming from these companies in the health care sector:

Sanofi (SNY - Analyst Report) has an earnings ESP of +2.27% and holds a Zacks Rank #3. Sanofi will report fourth quarter earnings on Feb 6.

Actavis plc (ACT - Analyst Report) has an earnings ESP of +0.66% and holds a Zacks Rank #1 (Strong Buy). Actavis will be reporting fourth quarter earnings on Feb 20.

Mallinckrodt plc (MNK - Snapshot Report) has an earnings ESP of +4.69% and holds a Zacks Rank #2 (Buy). Mallinckrodt will report first quarter fiscal 2014 earnings on Feb 6.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%